Mbx Biosciences, Inc. (MBX) intrinsic value & 10-year financials
Mbx Biosciences, Inc. (MBX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $49.61
- Market cap
- $1.8B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -44.8%
- Free cash flow (FY2025)
- -$81.9M
MBX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$87.0M | -$2.38 | -$81.9M | — | -39.0% |
| FY2024 | — | -$61.9M | -$5.82 | -$55.6M | — | -129.6% |
| FY2023 | — | -$32.6M | -$3.20 | -$32.1M | — | 34.3% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MBX Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MBX Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -44.7% ROIC.
MBX Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
MBX Biosciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.